LiDCO : Japan reimbursement for LiDCOrapidv2 disposables

LiDCO Group Plc

("LiDCO" or the "Company")

Reimbursement approval in Japan for LiDCOrapid v2disposables

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, announces that approval has been obtained for reimbursement in Japan of its single patient disposable kit (which contains an Argon pressure transducer and a LiDCO Smart Card) with effect from the beginning of June 2015.

This reimbursement follows Japanese product approval for the LiDCOrapid v2 with Unity software and continuous non-invasive blood pressure module announced in March 2015.

LiDCO's single patient disposable kit will be reimbursed at the same rate as the existing disposable product for arterial line minimally invasive hemodynamic monitoring in the Japanese market, while offering Japanese customers the option of the additional parameter of continuous non-invasive blood pressure.

Dr Terry O'Brien, CEO of LiDCO, commented: "We are delighted to have achieved registration and reimbursement in Japan of our multiparameter LiDCOrapidv2 with Unity software with continuous non-invasive blood pressure. The additional functionality and flexibility of our new product particularly addresses the monitoring of high-risk surgery patients now throughout their entire stay in the hospital. Our flexible LiDCO smart card allows us to offer this additional non-invasive functionality as and when required. Transitions between continuous non-invasive blood pressure to more invasive arterial line monitoring can be made with ease.

"Japan is a key territory for LiDCO as it is the second largest market in the world for our products, with approximately 680,000 high-risk surgical patients per annum. The availability of our multiparameter LiDCOrapidv2 with Unity software and continuous non-invasive blood pressure monitoring will help differentiate our product offering and build our market share in Japan."

For further information, please contact:

About LiDCO Group Plc (www.lidco.com)

LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.

Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus : a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).

LiDCOrapid : a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:

· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· quantification of hemodynamic response

· guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview : an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

LiDCO Unity Software: software incorporated into LiDCOrapid v2 that allows the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter ('BISTM')*and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.

*BIS TM and Bispectral Index are trademarks of Covidien LP registered in the US and foreign countries.

**CNAPTM is a trademark of CNSystems Medizintechnik AG.

LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.

LiDCO Distribution Network :

LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.

LiDCO's marketing office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM.